½ÃÀ庸°í¼­
»óǰÄÚµå
1621540

¼¼°èÀÇ Æ®·£½ºÆå¼Ç ±â¼ú ½ÃÀå : Á¦Ç°, ¹æ¹ý, ±â¼ú, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚº° ¿¹Ãø(2025-2030³â)

Transfection Technologies Market by Product (Instrument, Reagent & Kits), Method (Cationic Lipid Transfection, Cotransfection, Electroporation), Technology, Applications, End-user - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 193 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Æ®·£½ºÆå¼Ç ±â¼ú ½ÃÀåÀº 2023³â¿¡ 12¾ï 2,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 13¾ï 5,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 9.97%·Î ¼ºÀåÇϰí, 2030³â¿¡´Â 23¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Æ®·£½ºÆå¼Ç ±â¼úÀº ÁøÇÙ ¼¼Æ÷¿¡ ÇÙ»êÀ» µµÀÔÇϰí À¯ÀüÀÚ ¹ßÇö, À¯ÀüÀÚ Ä§¹¬, À¯ÀüÀÚ ÆíÁýÀ» ÃËÁøÇÏ´Â µ¥ »ç¿ëµÇ´Â ´Ù¾çÇÑ ¹æ¹ýÀ» Æ÷ÇÔÇÕ´Ï´Ù. À¯ÀüÀÚ ¿¬±¸, Ä¡·á °³¹ß¿¡ Áß¿äÇÑ ¿ªÇÒ ºñ±³Àû ºÐÀÚ »ý¹°ÇÐ, À¯ÀüÇÐ, »ý¹°ÀÇÇÐ ¿¬±¸¿¡ À־ ±ÍÁßÇÑ ÅøÀÌ µÇ°í ÀÖ½À´Ï´Ù. »ýüºÐÀÚ±¸Á¶ÀÇ Áøº¸, À¯ÀüÀÚÄ¡·á¿Í ¼¼Æ÷±â¹Ý ¿¬±¸¿¡¼­ÀÇ ÀÚ±ÝÁ¶´Þ Áõ°¡, ÇÕ¼º»ý¹°ÇÐ ÀÀ¿ë ¼ö¿ä Áõ°¡ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ¹ÙÀÌ·¯½º¼º Æ®·£½ºÆå¼Ç¹ýÀÇ °³¹ß, Æ®·£½ºÆå¼ÇÀÌ °ï¶õÇÑ ¼¼Æ÷¿¡ÀÇ Æ®·£½ºÆå¼Ç¿¡ ÀÖ¾î, ±â¾÷ÀÌ Àü·«Àû ÅõÀÚ³ª °øµ¿ ¿¬±¸¸¦ ÅëÇØ Ÿ°ÙÀ¸·Î ÇØ¾ß ÇÒ ½ÅÈï±¹ ½ÃÀåÀ» ³ªÅ¸³»°í ÀÖ½À´Ï´Ù. ÃÊ´ë ¼¼Æ÷ ¶Ç´Â in vivo Á¶°Ç ÇÏ¿¡¼­ÀÇ Àü´Þ È¿À²ÀÌ ÁÁÁö ¾ÊÀº °úÁ¦´Â ½ÃÀå ¼ºÀå¿¡ Å« Á¦¾àÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ¼¼Æ÷ µ¶¼º ÃÖ¼ÒÈ­, »õ·Î¿î Àü´Þ º¤ÅÍ °³¹ß, Æ®·£½ºÆå¼Ç °á°ú¸¦ ¿¹ÃøÇϰí ÃÖÀûÈ­ÇϱâÀ§ÇÑ AI ÅëÇÕ¿¡ ÃÊÁ¡À» ¸ÂÃß¾î¾ßÇÕ´Ï´Ù. ޱ¸´Â ÀáÀçÀûÀÎ ¼ºÀåÀÇ ±æÀ» º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù. ½ÃÀå °æÀïÀº ¿©ÀüÈ÷ Ä¡¿­Çϰí Áö¹èÀûÀÎ ±â¾÷ÀÌ °­ÇÑ ¹ßÆÇÀ» ±¸ÃàÇϰí ÀÖÁö¸¸, Çõ½ÅÀûÀÎ ¼Ö·ç¼ÇÀ» °®Ãá ½Å±Ô¡¤½ÅÈï ±â¾÷ÀÌ ½ÃÀåÀÇ Áß¿äÇÑ Æ´»õ¸¦ ¿©´Â ¿©Áö°¡ ÀÖ½À´Ï´Ù. ±â¼úÀÇ Áøº¸³ª ±ÔÁ¦ÀÇ °³¹ß¿¡ ¸ÂÃß¾î Á¾ÇÕÀûÀΠǰÁú º¸ÁõÀ» ä¿ëÇØ, ÃÖÁ¾ »ç¿ëÀÚ¿ëÀÇ ±³À°À̳ª ¼­Æ÷Æ® ¼­ºñ½º¸¦ °­È­ÇÏ´Â °ÍÀÌ, Æ®·£½ºÆå¼Ç ±â¼ú ½ÃÀåÀÇ À¯¸ÁÇÑ ¼ºÀå ±Ëµµ¸¦ Ȱ¿ëÇϴµ¥ À־ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 12¾ï 2,000¸¸ ´Þ·¯
¿¹Ãø³â(2024) 13¾ï 5,000¸¸ ´Þ·¯
¿¹Ãø³â(2030) 23¾ï 9,000¸¸ ´Þ·¯
CAGR(%) 9.97%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â Æ®·£½ºÆå¼Ç ±â¼ú ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

Æ®·£½ºÆå¼Ç ±â¼ú ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ ¾ò´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ À§ÇèÀ» ¿ÏÈ­ÇÒ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ´õ ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¸ÂÃãÇü ÀÇ·á ¹× ¹ÙÀÌ¿À ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
    • ½Å±Ô ºñ¹ÙÀÌ·¯½º Àü´Þ ½Ã½ºÅÛÀÇ °³¹ß°ú »ó¾÷Àû Ä¡·á ÀÀ¿ëÀ» À§ÇÑ ÇÁ·Î¼¼½ºÀÇ ½ºÄÉÀϾ÷
    • Æ®·£½ºÆå¼Ç ±â¼ú¿¡ À־ÀÇ ¿¬±¸°³¹ßÀ» À§ÇÑ °øÀû ¹× ¹Î°£ ÀÚ±Ý Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • °í±Þ Æ®·£½ºÆå¼Ç ±â¼ú ¹× °ü·Ã Á¦Ç°ÀÇ »ó´ëÀûÀ¸·Î ³ôÀº ºñ¿ë
  • ½ÃÀå ±âȸ
    • mRNA ¹é½ÅÀÇ °³¹ßÀÌ ÁøÇàµÇ°í Àֱ⠶§¹®¿¡ ´ë·® »ý»êÀÌ °¡´ÉÇÑ °ß°íÇÑ Æ®·£½ºÆå¼Ç ½Ã½ºÅÛÀÌ ÇÊ¿äÇÏ´Ù
    • ƯÁ¤ ¼¼Æ÷ À¯ÇüÀ̳ª ¿ëµµ¿¡ ¸ÂÃá, ´Ù¿ëµµ·Î Ä¿½ºÅ͸¶ÀÌÁî °¡´ÉÇÑ Æ®·£½ºÆå¼Ç ½Ã¾àÀ̳ª ÀåÄ¡ÀÇ °³¹ß
  • ½ÃÀåÀÇ °úÁ¦
    • À¯ÀüÀÚ Ä¡·á Á¦Ç°°ú Æ®·£½ºÆå¼Ç ±â¼ú¿¡ ´ëÇÑ ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç

Porter's Five Force : Æ®·£½ºÆå¼Ç ±â¼ú ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Force Framework´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. ´ç½ÅÀº ´õ °­ÀÎÇÑ ½ÃÀå¿¡¼­ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : Æ®·£½ºÆå¼Ç ±â¼ú ½ÃÀå¿¡¼­ ¿ÜºÎ·ÎºÎÅÍÀÇ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº Æ®·£½ºÆå¼Ç ±â¼ú ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ¾ÕÀ» ³»´Ùº» Àû±ØÀûÀÎ ÀÇ»ç°áÁ¤À» ÇÒ Áغñ°¡ µÇ¾î ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : Æ®·£½ºÆå¼Ç ±â¼ú ½ÃÀå¿¡¼­ °æÀï ±¸µµ ÆÄ¾Ç

Æ®·£½ºÆå¼Ç ±â¼ú ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀå ÁýÁß, ´ÜÆíÈ­ ¹× ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í °ø±Þ¾÷ü´Â °æÀïÀÌ Ä¡¿­ ÇØÁü¿¡ µû¶ó ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÕ´Ï´Ù. Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : Æ®·£½ºÆå¼Ç ±â¼ú ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â Æ®·£½ºÆå¼Ç ±â¼ú ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡Çϱâ À§ÇÑ Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ºÐÇÒÇϰí Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ : Æ®·£½ºÆå¼Ç ±â¼ú ½ÃÀå¿¡¼­ ¼º°øÀ» À§ÇÑ ±æÀ» ±×¸®±â

Æ®·£½ºÆå¼Ç ±â¼ú ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÇÁ·¹Á𽺠°­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÎ ¿ä¼ÒÀÔ´Ï´Ù. ÀÌ Á¢±Ù¹ýÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ: ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­: ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ¸ÂÃãÇü ÀÇ·á ¹× ¹ÙÀÌ¿À ÀǾàǰ ¼ö¿ä Áõ°¡
      • ½Å±Ô ºñ¹ÙÀÌ·¯½º¼º Àü´Þ ½Ã½ºÅÛÀÇ °³¹ß°ú »ó¾÷ Ä¡·á¿¡ÀÇ ÀÀ¿ëÀ» À§ÇÑ ÇÁ·Î¼¼½ºÀÇ ½ºÄÉÀÏ ¾÷
      • Æ®·£½ºÆå¼Ç ±â¼ú¿¡ À־ÀÇ ¿¬±¸°³¹ß¿¡ÀÇ °øÀû Àڱݰú ¹Î°£ ÀÚ±Ý Áõ°¡
    • ¾ïÁ¦¿äÀÎ
      • ÷´Ü Æ®·£½ºÆå¼Ç ±â¼ú ¹× °ü·Ã Á¦Ç°ÀÇ ºñ¿ëÀÌ ºñ±³Àû ³ô´Ù
    • ±âȸ
      • mRNA ¹é½ÅÀÇ Áö¼ÓÀûÀÎ °³¹ß¿¡´Â ´ë±Ô¸ð »ý»ê ¿ä±¸¸¦ ÃæÁ·½Ãų ¼ö ÀÖ´Â °ß°íÇÑ Æ®·£½ºÆå¼Ç ½Ã½ºÅÛÀÌ ÇÊ¿äÇß½À´Ï´Ù.
      • ƯÁ¤ ¼¼Æ÷ À¯Çü ¹× ¿ëµµ¿¡ ¸Â´Â ´Ù¿ëµµ·Î »ç¿ëÀÚ Á¤ÀÇ °¡´ÉÇÑ Æ®·£½ºÆå¼Ç ½Ã¾à ¹× ÀåÄ¡ °³¹ß
    • °úÁ¦
      • À¯ÀüÀÚ Ä¡·á Á¦Ç°¿¡ ´ëÇÑ ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç°ú Æ®·£½ºÆå¼Ç ±â¼ú
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
    • ¹æ¹ý : ºñ¿ë È¿À²¿¡ ÀÇÇÑ ½Ã¾à ±â¹Ý ¹æ¹ýÀÇ Á߿伺 Áõ°¡
    • ¿ëµµ: ¹ÙÀÌ¿ÀÀǾàǰ °³¹ß¿¡ À־ÀÇ ´Ü¹éÁú »ý»êÀÇ ´Ù¾çÇÑ ¿ëµµ
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »ç±³
    • ±â¼úÀû
    • ¹ý·ü»ó
    • ȯ°æ

Á¦6Àå Æ®·£½ºÆå¼Ç ±â¼ú ½ÃÀå : Á¦Ç°º°

  • ±â±â
  • ½Ã¾à ¹× ŰƮ

Á¦7Àå Æ®·£½ºÆå¼Ç ±â¼ú ½ÃÀå : ¹æ¹ýº°

  • ¾çÀ̿ ÁöÁú Æ®·£½ºÆå¼Ç
  • °øÆ®·£½ºÆå¼Ç
  • ÀÏ·ºÆ®·ÎÆ÷·¹À̼Ç
  • »ýü³» Æ®·£½ºÆå¼Ç
  • ¸®Æ÷Æå¼Ç
  • ´ºÅ¬·¹¿ÀÆå¼Ç

Á¦8Àå Æ®·£½ºÆå¼Ç ±â¼ú ½ÃÀå : ±â¼úº°

  • »ýÈ­ÇÐ º£À̽º Æ®·£½ºÆå¼Ç
  • ¹°¸®Àû Æ®·£½ºÆå¼Ç
  • ¹ÙÀÌ·¯½º º¤ÅÍ º£À̽º Æ®·£½ºÆå¼Ç

Á¦9Àå Æ®·£½ºÆå¼Ç ±â¼ú ½ÃÀå : ¿ëµµº°

  • ¹ÙÀÌ¿À¸ÞµðÄà Á¶»ç
  • À¯ÀüÀÚ Ä§¹¬
  • ´Ü¹éÁú »ý»ê
  • ¾ÈÁ¤ ¼¼Æ÷ÁÖ »ý¼º
  • Áٱ⼼Æ÷ÀÇ ÀçÇÁ·Î±×·¡¹Ö°ú ºÐÈ­
  • Ä¡·á ½Ç½Ã
  • ¹ÙÀÌ·¯½º »ý»ê

Á¦10Àå Æ®·£½ºÆå¼Ç ±â¼ú ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • Çмú¿¬±¸±â°ü
  • °è¾à¿¬±¸±â°ü
  • Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷

Á¦11Àå ¾Æ¸Þ¸®Ä«ÀÇ Æ®·£½ºÆå¼Ç ±â¼ú ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦12Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Æ®·£½ºÆå¼Ç ±â¼ú ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦13Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Æ®·£½ºÆå¼Ç ±â¼ú ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦14Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
    • Polyplus, »õ·Î¿î DOE ¼­ºñ½º ¿É¼ÇÀ» °®Ãá FectoVIR-LV Æ®·£½ºÆå¼Ç ½Ã¾àÀ» ¹ß¸Å
    • BioCentriq¿Í KytopenÀÌ Á¦ÈÞ¸¦ È®´ëÇØ Çõ½ÅÀûÀÎ À¯ÀüÀÚ ÆíÁý ±â¼úÀÌ ¼¼Æ÷ Ä¡·á Á¦Á¶¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» °¡¼Ó
    • Avectas, ºñ±³ÇÒ ¼ö ¾ø´Â ¼¼Æ÷ÀÇ °Ç°­°ú ±â´É¼ºÀ» °®Ãá Â÷¼¼´ë À¯ÀüÀÚ ÀçÁ¶ÇÕ ¼¼Æ÷ Ä¡·áÀÇ ÀÓ»ó Á¦Á¶¸¦ À§ÇÑ Solupore PlatformÀ» ¹ßÇ¥
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸ñ·Ï

  • Agilent Technologies, Inc.
  • Akron Biotech
  • Altogen Biosystems
  • Bio-Rad Laboratories, Inc.
  • Biomol GmbH
  • Epoch Life Science
  • F. Hoffmann-La Roche AG
  • FUJIFILM Wako Pure Chemical Corporation
  • Geno Technology, Inc.
  • Lonza Group
  • Maxcyte Inc.
  • Merck KGaA
  • Mirus Bio
  • OriGene Technologies, Inc.
  • OZ Biosciences SAS
  • Polyplus-transfection SA by Sartorius AG
  • Polysciences, Inc.
  • Promega Corporation
  • Qiagen NV
  • Reprocell Inc.
  • SignaGen Laboratories
  • Takara Bio Inc.
  • Thermo Fisher Scientific, Inc.
  • VWR International, LLC by Avantor
JHS 25.01.02

The Transfection Technologies Market was valued at USD 1.22 billion in 2023, expected to reach USD 1.35 billion in 2024, and is projected to grow at a CAGR of 9.97%, to USD 2.39 billion by 2030.

Transfection technologies encompass a range of methods used to introduce nucleic acids into eukaryotic cells, facilitating gene expression, gene silencing, or genome editing. The necessity of these technologies lies in their critical role in drug discovery, genetic research, and therapeutic development, making them invaluable tools in molecular biology, genetics, and biomedical research. Applications span across gene expression studies, protein production, and development of gene therapies, with significant end-use in pharmaceuticals, academic research institutions, and biotechnology firms. Key growth influences include advancements in biomolecular structures, increased funding in gene therapy and cell-based research, and rising demand for synthetic biology applications. Recent potential opportunities lie in CRISPR technology enhancements, development of non-viral transfection methods, and transfection in difficult-to-transfect cells, representing emerging markets that companies should target through strategic investments and collaborations. However, challenges such as high costs, cytotoxicity of certain reagents, and delivery inefficiency in primary cells or in vivo conditions pose significant limitations to market growth. Intellectual property issues and stringent regulatory frameworks further complicate market dynamics. Innovation should focus on enhancing transfection efficiency, minimizing cytotoxicity, developing novel delivery vectors, and integrating AI to predict and optimize transfection outcomes. Additionally, exploring biodegradable polymers and nanotechnology-based delivery systems presents potential growth avenues. The market nature remains competitive with strong footholds of dominant players yet offers space for novel and emerging companies equipped with innovative solutions to carve out significant market niches. Overall, aligning with technological advancements and regulatory developments, adopting comprehensive quality assurance, and enhancing educational and support services for end users will be crucial in capitalizing on the promising growth trajectory of the transfection technologies market.

KEY MARKET STATISTICS
Base Year [2023] USD 1.22 billion
Estimated Year [2024] USD 1.35 billion
Forecast Year [2030] USD 2.39 billion
CAGR (%) 9.97%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Transfection Technologies Market

The Transfection Technologies Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising demand for personalized medicine and biopharmaceuticals
    • Development of novel, non-viral delivery systems and scaling up processes for commercial therapeutic applications
    • Increased public and private funding for research and development in transfection technologies
  • Market Restraints
    • Relatively high cost of advanced transfection technologies and related products
  • Market Opportunities
    • Ongoing development of mRNA vaccines necessitated robust transfection systems capable for large-scale production needs
    • Development of versatile and customizable transfection reagents and equipment tailored for specific cell types and applications
  • Market Challenges
    • Stringent regulatory requirements for gene therapy products and transfection technologies

Porter's Five Forces: A Strategic Tool for Navigating the Transfection Technologies Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Transfection Technologies Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Transfection Technologies Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Transfection Technologies Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Transfection Technologies Market

A detailed market share analysis in the Transfection Technologies Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Transfection Technologies Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Transfection Technologies Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Transfection Technologies Market

A strategic analysis of the Transfection Technologies Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Transfection Technologies Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., Akron Biotech, Altogen Biosystems, Bio-Rad Laboratories, Inc., Biomol GmbH, Epoch Life Science, F. Hoffmann-La Roche AG, FUJIFILM Wako Pure Chemical Corporation, Geno Technology, Inc., Lonza Group, Maxcyte Inc., Merck KGaA, Mirus Bio, OriGene Technologies, Inc., OZ Biosciences SAS, Polyplus-transfection SA by Sartorius AG, Polysciences, Inc., Promega Corporation, Qiagen NV, Reprocell Inc., SignaGen Laboratories, Takara Bio Inc., Thermo Fisher Scientific, Inc., and VWR International, LLC by Avantor.

Market Segmentation & Coverage

This research report categorizes the Transfection Technologies Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Instrument and Reagent & Kits.
  • Based on Method, market is studied across Cationic Lipid Transfection, Cotransfection, Electroporation, In Vivo Transfection, Lipofection, and Nucleofection.
  • Based on Technology, market is studied across Biochemical Based Transfection, Physical Transfection, and Viral-Vector Based Transfection.
  • Based on Applications, market is studied across Bio-Medical Research, Gene Silencing, Protein Production, Stable Cell Line Generation, Stem Cell Reprogramming & Differentiation, Therapeutic Delivery, and Virus Production.
  • Based on End-user, market is studied across Academic & Research Institutes, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising demand for personalized medicine and biopharmaceuticals
      • 5.1.1.2. Development of novel, non-viral delivery systems and scaling up processes for commercial therapeutic applications
      • 5.1.1.3. Increased public and private funding for research and development in transfection technologies
    • 5.1.2. Restraints
      • 5.1.2.1. Relatively high cost of advanced transfection technologies and related products
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing development of mRNA vaccines necessitated robust transfection systems capable for large-scale production needs
      • 5.1.3.2. Development of versatile and customizable transfection reagents and equipment tailored for specific cell types and applications
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirements for gene therapy products and transfection technologies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Method: Rising significance of reagent-based methods due to cost effectiveness
    • 5.2.2. Application: Diverse applications in protein production in biopharmaceutical development
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Transfection Technologies Market, by Product

  • 6.1. Introduction
  • 6.2. Instrument
  • 6.3. Reagent & Kits

7. Transfection Technologies Market, by Method

  • 7.1. Introduction
  • 7.2. Cationic Lipid Transfection
  • 7.3. Cotransfection
  • 7.4. Electroporation
  • 7.5. In Vivo Transfection
  • 7.6. Lipofection
  • 7.7. Nucleofection

8. Transfection Technologies Market, by Technology

  • 8.1. Introduction
  • 8.2. Biochemical Based Transfection
  • 8.3. Physical Transfection
  • 8.4. Viral-Vector Based Transfection

9. Transfection Technologies Market, by Applications

  • 9.1. Introduction
  • 9.2. Bio-Medical Research
  • 9.3. Gene Silencing
  • 9.4. Protein Production
  • 9.5. Stable Cell Line Generation
  • 9.6. Stem Cell Reprogramming & Differentiation
  • 9.7. Therapeutic Delivery
  • 9.8. Virus Production

10. Transfection Technologies Market, by End-user

  • 10.1. Introduction
  • 10.2. Academic & Research Institutes
  • 10.3. Contract Research Organizations
  • 10.4. Pharmaceutical & Biotechnology Companies

11. Americas Transfection Technologies Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Transfection Technologies Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Transfection Technologies Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Polyplus Launches FectoVIR-LV Transfection Reagent with New DOE Service Options
    • 14.3.2. BioCentriq and Kytopen Expand Partnership to Expedite Impact of Transformative Gene-Editing Technology on Cell Therapy Manufacturing
    • 14.3.3. Avectas Launches the Solupore Platform for the Clinical Manufacturing of Next- Generation Gene-Modified Cell Therapies with Unparalleled Cell Health and Functionality
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Agilent Technologies, Inc.
  • 2. Akron Biotech
  • 3. Altogen Biosystems
  • 4. Bio-Rad Laboratories, Inc.
  • 5. Biomol GmbH
  • 6. Epoch Life Science
  • 7. F. Hoffmann-La Roche AG
  • 8. FUJIFILM Wako Pure Chemical Corporation
  • 9. Geno Technology, Inc.
  • 10. Lonza Group
  • 11. Maxcyte Inc.
  • 12. Merck KGaA
  • 13. Mirus Bio
  • 14. OriGene Technologies, Inc.
  • 15. OZ Biosciences SAS
  • 16. Polyplus-transfection SA by Sartorius AG
  • 17. Polysciences, Inc.
  • 18. Promega Corporation
  • 19. Qiagen NV
  • 20. Reprocell Inc.
  • 21. SignaGen Laboratories
  • 22. Takara Bio Inc.
  • 23. Thermo Fisher Scientific, Inc.
  • 24. VWR International, LLC by Avantor
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦